Decrease in Total Assets Due to a Decrease in Cash and Deposits
First written in FY2018-Q3. 20 of 28 entries say "Reframed", first in FY2019-Q1. Latest entry: 2026-08-06.
Stella Chemifa moved to the "Worse" side of this theme in 2022.
The whole theme swung hardest in 2021: 1 of 6 companies on the "Worse" side.
0 other companies' latest entry also says "Reframed".
- FY2026-H1RestatedAnnual report
「Total assets at the end of the interim consolidated accounting period were ¥6,087.1 million, an increase of ¥14.6 million from the end of the previous consolidated fiscal year. The main factors were increases in notes and accounts receivable and property, plant and equipment, despite a decrease in investments and other assets.」
Total assets increased slightly, mainly due to increases in notes and accounts receivable and property, plant and equipment. - FY2025ReframedAnnual report
「Total assets at the end of the current consolidated fiscal year were ¥6,072.5 million, an increase of ¥210.7 million from the end of the previous consolidated fiscal year. The main factors were increases in current assets and property, plant and equipment.」
While assets previously increased mainly due to an increase in property, plant and equipment, total assets increased by ¥210.7 million in the current fiscal year due to increases in both current assets and property, plant and equipment. - FY2025-H1ReframedAnnual report
「Total assets at the end of the interim consolidated accounting period were ¥5,969.1 million, an increase of ¥107.2 million from the end of the previous consolidated fiscal year. The main factors were increases in notes and accounts receivable and property, plant and equipment, respectively.」
Total assets increased by ¥1,072 million from the end of the previous consolidated fiscal year, with increases in notes and accounts receivable and property, plant and equipment cited as the main factors. - FY2024ReframedAnnual report
「Total assets at the end of the current consolidated fiscal year were ¥5,861.8 million, an increase of ¥314.6 million from the end of the previous consolidated fiscal year. The main factor was an increase in property, plant and equipment.」
While changes in total assets had previously been explained mainly by changes in cash and deposits and other items, they increased by ¥314.6 million in the current fiscal year, mainly due to an increase in property, plant and equipment. - FY2024-Q2ReframedAnnual report
「Total assets at the end of the second quarter of the current consolidated fiscal year were ¥5,802.3 million, an increase of ¥255.2 million from the end of the previous consolidated fiscal year. The main factors were increases in cash and deposits and property, plant and equipment due to the renewal of production facilities in the semiconductor division related to the high-purity chemicals business, respectively.」
Total assets increased by ¥255.2 million from the end of the previous fiscal year, with increases in cash and deposits and property, plant and equipment from the renewal of production facilities in the semiconductor division cited as the main factors. - FY2024-Q1ReframedAnnual report
「Total assets at the end of the first quarter of the current consolidated fiscal year were ¥5,654.8 million, an increase of ¥107.6 million from the end of the previous consolidated fiscal year. The main factor was an increase in cash and deposits, among other factors.」
Although total assets decreased at the end of the previous consolidated fiscal year mainly due to a decline in current assets, they increased by ¥107.6 million in the current quarter, mainly due to an increase in cash and deposits. - FY2023ReframedAnnual report
「Total assets at the end of the current consolidated fiscal year were ¥5,547.1 million, a decrease of ¥112.6 million from the end of the previous consolidated fiscal year. The main factor was a decrease in current assets.」
The explanation has changed from the previous fiscal year, when an increase in assets due to STELLA PHARMA CORPORATION's listing and other factors was disclosed, to a decrease in total assets in the current fiscal year mainly due to a decline in current assets. The breakdown cites decreases in cash and deposits and accounts receivable. - FY2023-Q3ReframedAnnual report
「Total assets at the end of the third quarter of the current consolidated fiscal year were ¥5,491.3 million, a decrease of ¥168.4 million from the end of the previous consolidated fiscal year. The main factors included decreases in cash and deposits, property, plant and equipment, and intangible assets, respectively.」
The explanation has changed from the previous quarter's disclosure of an increase in assets due to STELLA PHARMA CORPORATION's listing and other factors to a decrease in assets mainly due to decreases in cash and deposits, property, plant and equipment, and intangible assets. - FY2023-Q2ReframedAnnual report
「Total assets at the end of the second quarter of the current consolidated fiscal year were ¥5,857.7 million, an increase of ¥197.9 million from the end of the previous consolidated fiscal year. The main factors included an increase in cash and deposits and an increase in property, plant and equipment due to investment in a research and development building and other factors.」
Total assets increased by ¥197.9 million from the end of the previous fiscal year, mainly due to increases in cash and deposits and property, plant and equipment from investment in a research and development building and other factors. - FY2023-Q1ReframedAnnual report
「Total assets at the end of the first quarter of the current fiscal year amounted to ¥5,649.5 million, a decrease of ¥102 million from the end of the previous consolidated fiscal year. The main factors were an increase in property, plant and equipment due to investment in a research and development building, offset by decreases in merchandise and finished goods, and raw materials and supplies.」
The explanation has changed from one focused on changes in cash and deposits and other items to a slight decrease in assets mainly due to an increase in property, plant and equipment from investment in a research and development building and decreases in merchandise, raw materials and other items. - FY2022-Q3ReframedAnnual report
「Total assets at the end of the third quarter of the current consolidated fiscal year were ¥5,709.2 million, an increase of ¥415.9 million from the end of the previous consolidated fiscal year. The main factors included an ¥88.9 million increase in cash and deposits and a ¥122.1 million increase in notes and accounts receivable resulting from a public offering and other factors accompanying the new listing of the Company's consolidated subsidiary, STELLA PHARMA CORPORATION.」
The explanation has changed from the previous disclosures of decreases in total assets to an increase of ¥415.9 million in total assets in the third quarter, mainly due to increases in cash and deposits and notes and accounts receivable. - FY2022-Q2RestatedAnnual report
「Total assets at the end of the second quarter of the current consolidated fiscal year were ¥5,822.0 million, an increase of ¥528.6 million from the end of the previous consolidated fiscal year. The main factors included a ¥332.0 million increase in cash and deposits resulting from a public offering and other factors accompanying the new listing of the Company's consolidated subsidiary, STELLA PHARMA CORPORATION.」
Total assets increased by ¥528.6 million from the end of the previous fiscal year, mainly due to an increase in cash and deposits from the public offering and other factors accompanying STELLA PHARMA CORPORATION's new listing. - FY2022-Q1ReframedAnnual report
「Total assets at the end of the first quarter of the current consolidated fiscal year were ¥5,664.3 million, an increase of ¥370.9 million from the end of the previous consolidated fiscal year. The main factors included a ¥315.3 million increase in cash and deposits resulting from a public offering and other factors accompanying the new listing of the Company's consolidated subsidiary, STELLA PHARMA CORPORATION.」
The explanation has changed from a decrease in total assets due to previous decreases in cash and deposits and other items to an increase in total assets mainly due to an increase in cash from the public offering and other factors accompanying STELLA PHARMA CORPORATION's new listing. - FY2021RestatedAnnual report
「Total assets at the end of the current consolidated fiscal year were ¥5,293.3 million, a decrease of ¥28.2 million from the end of the previous consolidated fiscal year. The main factors were decreases in property, plant and equipment, intangible assets, and investments and other assets.」
Total assets decreased by ¥28.2 million from the end of the previous fiscal year, with the composition for the full year indicating that the main factors were decreases in fixed assets and other items. - FY2021-Q3ReframedAnnual report
「Total assets at the end of the third quarter of the current consolidated fiscal year were ¥5,206.4 million, a decrease of ¥115.2 million from the end of the previous consolidated fiscal year. The main factors were decreases in property, plant and equipment, intangible assets, and investments and other assets, respectively.」
Total assets decreased by ¥115.2 million from the end of the previous consolidated fiscal year, with decreases in property, plant and equipment, intangible assets, and investments and other assets cited as the main factors rather than the previous decreases in cash, trade receivables and other items. - FY2021-Q2ReframedAnnual report
「Total assets at the end of the second quarter of the current consolidated fiscal year were ¥5,146.0 million, a decrease of ¥175.5 million from the end of the previous consolidated fiscal year. The main factor was a decrease in merchandise and finished goods, among other factors.」
Total assets decreased by ¥175.5 million from the end of the previous consolidated fiscal year, but the main factor cited was a decrease in merchandise and finished goods rather than the previous decreases in cash and deposits and trade receivables. - FY2021-Q1RestatedAnnual report
「Total assets at the end of the first quarter of the current consolidated fiscal year were ¥5,177.5 million, a decrease of ¥144.1 million from the end of the previous consolidated fiscal year. The main factor was a decrease in cash and deposits, among other factors.」
Total assets decreased by ¥144.1 million from the end of the previous consolidated fiscal year, mainly due to a decline in cash and deposits. - FY2020RestatedAnnual report
「Total assets at the end of the current consolidated fiscal year were ¥5,321.6 million, a decrease of ¥223.8 million from the end of the previous consolidated fiscal year. The main factors were decreases in cash and deposits and notes and accounts receivable.」
The full-year disclosure also cites a decrease in total assets mainly due to decreases in cash and deposits and notes and accounts receivable. - FY2020-Q3RestatedAnnual report
「Total assets at the end of the third quarter of the current consolidated fiscal year were ¥5,106.1 million, a decrease of ¥439.3 million from the end of the previous consolidated fiscal year. The main factors were decreases in cash and deposits and notes and accounts receivable, respectively.」
Total assets decreased by ¥439.3 million from the end of the previous consolidated fiscal year, mainly due to decreases in cash and deposits and notes and accounts receivable. - FY2020-Q2ReframedAnnual report
「Total assets at the end of the second quarter of the current consolidated fiscal year were ¥5,217.7 million, a decrease of ¥327.7 million from the end of the previous consolidated fiscal year. The main factors were decreases in cash and deposits and notes and accounts receivable, respectively.」
Total assets decreased by ¥327.7 million from the end of the previous consolidated fiscal year, with decreases in cash and deposits as well as notes and accounts receivable cited as factors. - FY2020-Q1ReframedAnnual report
「Total assets at the end of the first quarter of the current consolidated fiscal year were ¥5,279.5 million, a decrease of ¥265.8 million from the end of the previous consolidated fiscal year. The main factor was a decrease in cash and deposits, among other factors.」
The explanation has changed from an increase in total assets driven by borrowings and improved free cash flow through the previous quarter to a decrease in total assets in the current quarter, mainly due to a decline in cash and deposits. - FY2019-Q3ReframedAnnual report
「Total assets at the end of the third quarter of the current consolidated fiscal year were ¥5,353.2 million, an increase of ¥215.8 million from the end of the previous consolidated fiscal year. The main factor was an increase in cash and deposits as free cash flow improved significantly with the rise in profit levels.」
The explanation of the main factor behind the increase in total assets has changed from an increase in cash from borrowings through the previous quarter to an improvement in free cash flow accompanying higher profit levels and an increase in cash and deposits. - FY2019-Q2RestatedAnnual report
「Total assets at the end of the second quarter of the current consolidated fiscal year were ¥5,348.6 million, an increase of ¥211.2 million from the end of the previous consolidated fiscal year. The main factor was an increase in cash and deposits following borrowings to secure working capital and an appropriate level of cash on hand.」
Total assets have increased from the end of the previous consolidated fiscal year, mainly due to an increase in cash and deposits from borrowings. - FY2019-Q1ReframedAnnual report
「Total assets at the end of the first quarter of the current consolidated fiscal year were ¥5,422.6 million, an increase of ¥285.2 million from the end of the previous consolidated fiscal year. The main factor was an increase in cash and deposits following borrowings to secure working capital and an appropriate level of cash on hand.」
The explanation has changed from a decrease in total assets caused by a decline in cash and deposits in the previous quarter to an increase in total assets in the current quarter, mainly due to an increase in cash and deposits from borrowings. - FY2018-Q3First statedAnnual report
「Total assets at the end of the third quarter of the current consolidated fiscal year amounted to ¥49,399 million, a decrease of ¥2,682 million from the end of the previous consolidated fiscal year. The main factor was a decline in cash and deposits.」
Total assets decreased by ¥2,682 million from the end of the previous consolidated fiscal year, primarily due to a decline in cash and deposits.